J M McKenney

Summary

Affiliation: National Clinical Research
Country: USA

Publications

  1. ncbi request reprint New cholesterol guidelines, new treatment challenges
    James M McKenney
    National Clinical Research, Inc, Richmond, VA, USA
    Pharmacotherapy 22:853-63. 2002
  2. doi request reprint Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review
    James M McKenney
    National Clinical Research, Inc, Richmond, VA 23294, USA
    Postgrad Med 124:7-20. 2012
  3. ncbi request reprint Statin safety: an assessment using an administrative claims database
    Mark J Cziraky
    HealthCore, Inc, Wilmington, Delaware 19801, USA
    Am J Cardiol 97:61C-68C. 2006
  4. ncbi request reprint An assessment of statin safety
    James M McKenney
    National Clinical Research, Inc, 2809 Emerywood Pkwy, Ste 140, Richmond, VA 23294, USA
    Am J Manag Care 12:S310-7. 2006
  5. doi request reprint Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy
    James M McKenney
    Virginia Commonwealth University and National Clinical Research, Inc, Richmond, USA
    J Am Coll Cardiol 59:2344-53. 2012
  6. pmc Indices of insulin sensitivity and secretion from a standard liquid meal test in subjects with type 2 diabetes, impaired or normal fasting glucose
    Kevin C Maki
    Provident Clinical Research, Bloomington, IN, USA
    Nutr J 8:22. 2009
  7. ncbi request reprint Efficacy and safety of rosuvastatin in treatment of dyslipidemia
    James M McKenney
    School of Pharmacy, Medical College of Virginia, Virginia Commonwealth University, Richmond, USA
    Am J Health Syst Pharm 62:1033-47. 2005
  8. ncbi request reprint Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks
    James M McKenney
    Virginia Commonwealth University and National Clinical Research, Richmond, Virginia 23294, USA
    Am J Cardiol 96:60E-66E. 2005
  9. ncbi request reprint Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia
    James McKenney
    National Clinical Research, Inc, Richmond, VA 23294, USA
    Curr Med Res Opin 21:1403-12. 2005
  10. ncbi request reprint Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin
    James M McKenney
    National Clinical Research Inc, 2809 Emerywood Parkway, Ste 140, Richmond, VA 23294, USA
    J Cardiovasc Pharmacol 46:594-9. 2005

Detail Information

Publications48

  1. ncbi request reprint New cholesterol guidelines, new treatment challenges
    James M McKenney
    National Clinical Research, Inc, Richmond, VA, USA
    Pharmacotherapy 22:853-63. 2002
    ....
  2. doi request reprint Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review
    James M McKenney
    National Clinical Research, Inc, Richmond, VA 23294, USA
    Postgrad Med 124:7-20. 2012
    ..Larger lipid studies as well as studies evaluating cardiovascular outcomes during atorvastatin plus niacin treatment are warranted...
  3. ncbi request reprint Statin safety: an assessment using an administrative claims database
    Mark J Cziraky
    HealthCore, Inc, Wilmington, Delaware 19801, USA
    Am J Cardiol 97:61C-68C. 2006
    ..No hospitalized cases of the index AEs were observed in study subjects during the 6-month period before initiation of the lipid-lowering drug. Statin monotherapy as currently prescribed is generally well tolerated and safe...
  4. ncbi request reprint An assessment of statin safety
    James M McKenney
    National Clinical Research, Inc, 2809 Emerywood Pkwy, Ste 140, Richmond, VA 23294, USA
    Am J Manag Care 12:S310-7. 2006
    ..Administrative claims data of hospitalization rates for adverse events in statin patients confirm the task force conclusion that, overall, statins are safe and well tolerated when used as monotherapy...
  5. doi request reprint Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy
    James M McKenney
    Virginia Commonwealth University and National Clinical Research, Inc, Richmond, USA
    J Am Coll Cardiol 59:2344-53. 2012
    ..Secondary objectives included evaluation of effects on other lipid parameters and the attainment of LDL-C treatment goals of <100 mg/dl (2.59 mmol/l) and <70 mg/dl (1.81 mmol/l)...
  6. pmc Indices of insulin sensitivity and secretion from a standard liquid meal test in subjects with type 2 diabetes, impaired or normal fasting glucose
    Kevin C Maki
    Provident Clinical Research, Bloomington, IN, USA
    Nutr J 8:22. 2009
    ..To provide an initial evaluation of insulin sensitivity and secretion indices derived from a standard liquid meal tolerance test protocol in subjects with normal (NFG), impaired fasting glucose (IFG) or type 2 diabetes mellitus...
  7. ncbi request reprint Efficacy and safety of rosuvastatin in treatment of dyslipidemia
    James M McKenney
    School of Pharmacy, Medical College of Virginia, Virginia Commonwealth University, Richmond, USA
    Am J Health Syst Pharm 62:1033-47. 2005
    ..The chemistry, pharmacology, pharmacokinetics, drug interactions, clinical efficacy, adverse effects, dosage and administration, and place in therapy of rosuvastatin are reviewed...
  8. ncbi request reprint Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks
    James M McKenney
    Virginia Commonwealth University and National Clinical Research, Richmond, Virginia 23294, USA
    Am J Cardiol 96:60E-66E. 2005
    ..67 mmol/L (26 mg/dL), reported no signals of untoward effects in patients with progressively lower levels...
  9. ncbi request reprint Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia
    James McKenney
    National Clinical Research, Inc, Richmond, VA 23294, USA
    Curr Med Res Opin 21:1403-12. 2005
    ....
  10. ncbi request reprint Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin
    James M McKenney
    National Clinical Research Inc, 2809 Emerywood Parkway, Ste 140, Richmond, VA 23294, USA
    J Cardiovasc Pharmacol 46:594-9. 2005
    ..Selecting the starting dose of atorvastatin using a treatment algorithm achieves NCEP ATP III LDL-cholesterol goals in the majority of patients and minimizes the need for dose titration...
  11. pmc LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD
    James McKenney
    National Clinic Research, Inc, Richmond, Virginia, USA
    MedGenMed 7:3. 2005
    ....
  12. ncbi request reprint Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force
    James M McKenney
    National Clinical Research, Virginia Commonwealth University, Richmond, Virginia 23294, USA
    Am J Cardiol 97:89C-94C. 2006
    ..Practical guidance in the form of recommendations to health professionals who manage the coronary artery disease risk of patients with statin therapy is provided...
  13. ncbi request reprint Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia
    James M McKenney
    National Clinical Research Inc, Richmond, Virginia 23294, USA
    J Am Coll Cardiol 47:1584-7. 2006
    ..This study sought to determine the long-term safety and efficacy of co-administered fenofibrate (FENO) and ezetimibe (EZE) in patients with mixed hyperlipidemia...
  14. ncbi request reprint Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin
    James M McKenney
    Virginia Commonwealth University, Richmond, Virginia, USA
    J Am Coll Cardiol 48:1782-90. 2006
    ..This study sought to evaluate the efficacy and safety of torcetrapib in patients with low high-density lipoprotein cholesterol (HDL-C) levels receiving background atorvastatin...
  15. ncbi request reprint Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)
    James M McKenney
    National Clinical Research, Richmond, VA 23227, United States
    Atherosclerosis 192:432-7. 2007
    ..No drug-related myopathy or hepatotoxicity was observed. In this study, low to moderate dose combination therapy with a statin and niacin ER provided broad control of lipids and lipoproteins independently associated with CHD...
  16. ncbi request reprint Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia
    James M McKenney
    Virginia Commonwealth University, Richmond, Virginia, USA
    Am J Health Syst Pharm 64:595-605. 2007
    ..A review of the key properties and trial results associated with prescription omega-3 fatty acids (P-O3FA) and a description of its place in the treatment of hypertriglyceridemia and coronary heart disease (CHD) risk are presented...
  17. ncbi request reprint Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia
    James M McKenney
    School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, USA
    Pharmacotherapy 27:715-28. 2007
    ..The availability of prescription omega-3 fatty acids, which ensures consistent quality and purity, should prove to be valuable for the medical management of hypertriglyceridemia...
  18. doi request reprint Safety of extended-release niacin/laropiprant in patients with dyslipidemia
    James McKenney
    National Clinical Research Inc, 2809 Emerywood Parkway, Suite 140, Richmond, VA 23294, USA
    J Clin Lipidol 4:105-112.e1. 2010
    ..To evaluate the safety profile of extended-release niacin/laropiprant (ERN/LRPT), pooling data from studies in the clinical development program...
  19. ncbi request reprint The National Lipid Association surveys of consumers, physicians, and pharmacists regarding an over-the-counter statin in the United States: is this a good idea?
    James M McKenney
    National Clinical Research, Inc, Richmond, Virginia 23294 3740, USA
    Am J Cardiol 94:16F-21F. 2004
    ..Although such support would require further training and time, pharmacists believed that they could facilitate consumer self-care programs and follow-up with physicians...
  20. ncbi request reprint Potential nontraditional applications of statins
    James M McKenney
    School of Pharmacy, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA, USA
    Ann Pharmacother 37:1063-71. 2003
    ....
  21. ncbi request reprint Pharmacotherapy of dyslipidemia
    J M McKenney
    School of Pharmacy, Medical College of Virginia, Virginia Commonwealth University, USA
    Cardiovasc Drugs Ther 15:413-22. 2001
    ..For severe hyperlipidemia that does not respond to single drug therapy, combination drug therapy may be required. This article reviews the various manifestations of dyslipidemia and assesses the most efficacious treatments...
  22. ncbi request reprint Pharmacologic characteristics of statins
    James M McKenney
    National Clinical Research, Inc, and School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, USA
    Clin Cardiol 26:III32-8. 2003
    ..As a product of the ongoing efforts regarding statin pharmacology, the new statin rosuvastatin exhibits significant improvements in several of these characteristics...
  23. ncbi request reprint Will torcetrapib be the next big thing in coronary heart disease risk reduction?
    James M McKenney
    National Clinical Research, 2809 Emerywood Parkway, Suite 140, Richmond, VA 23294, USA
    Curr Atheroscler Rep 9:48-56. 2007
    ..The drug appears to be well tolerated. Large surrogate and survival outcome trials are underway to document its impact on CHD...
  24. ncbi request reprint Combination therapy for elevated low-density lipoprotein cholesterol: the key to coronary artery disease risk reduction
    Jim McKenney
    National Clinical Research, Richmond, Virginia 23294, USA
    Am J Cardiol 90:8K-20K. 2002
    ..This article reviews the use of combination therapy for the management of elevated LDL cholesterol, highlighting important therapy considerations...
  25. ncbi request reprint Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial
    James M McKenney
    National Clinical Research, Richmond, Virginia, USA
    Curr Med Res Opin 19:689-98. 2003
    ..0 mmol/l [< 266 mg/dl] to < 2.0 mmol/l [< 177 mg/dl]), and the total cholesterol/high-density lipoproteincholesterol ratio (< 4 to < 7) (70% to 83% versus 35% to 79%)...
  26. ncbi request reprint Optimizing LDL-C lowering with statins
    James M McKenney
    Virginia Commonwealth University and National Clinical Research, 2809 Emerywood Parkway, Suite 140, Richmond, VA 23294, USA
    Am J Ther 11:54-9. 2004
    ..Of these approaches, use of a more efficacious statin is preferred to combination therapy because of cost, safety, effectiveness, and simplicity issues...
  27. ncbi request reprint New guidelines for managing hypercholesterolemia
    J M McKenney
    School of Pharmacy, Medical College of Virginia, Virginia Commonwealth University, and National Clinical Research, Richmond 23294, USA
    J Am Pharm Assoc (Wash) 41:596-607. 2001
    ..To summarize for pharmacists the Adult Treatment Panel III (ATP III), recently issued guidelines for managing hypercholesterolemia, from the National Cholesterol Education Program (NCEP)...
  28. ncbi request reprint New perspectives on the use of niacin in the treatment of lipid disorders
    James McKenney
    National Clinical Research and Virginia Commonwealth University, Richmond, USA
    Arch Intern Med 164:697-705. 2004
    ..Extended-release niacin, also given once daily, has an absorption rate intermediate between the other formulations and is associated with fewer flushing and gastrointestinal symptoms without increasing hepatotoxic risk...
  29. ncbi request reprint Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia
    J M McKenney
    School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, USA
    Am J Cardiol 88:270-4. 2001
    ..Atorvastatin had a preferred LDL effect, whereas niacin had a preferred high-density lipoprotein effect...
  30. ncbi request reprint Update on the National Cholesterol Education Program Adult Treatment Panel III guidelines: getting to goal
    James M McKenney
    National Clinical Research, Inc, Richmond, Virginia 23294, USA
    Pharmacotherapy 23:26S-33S. 2003
    ..Overall, ATP III represents an aggressive approach to treating dyslipidemia, greatly extending the number of individuals who qualify for treatment...
  31. ncbi request reprint National survey of pharmacists about coronary heart disease, hypercholesterolemia, nonprescription statintherapy, and pharmacists' services
    James M McKenney
    National Clinical Research, Richmond, VA 23294, USA
    J Am Pharm Assoc (2003) 44:562-8. 2004
    ....
  32. ncbi request reprint Niacin for dyslipidemia: considerations in product selection
    James McKenney
    National Clinical Research, 2809 Emerywood Parkway, Suite 140, Richmond, VA 23294, USA
    Am J Health Syst Pharm 60:995-1005. 2003
    ..Several niacin products are available with significant differences in their safety and efficacy profiles. Health care providers must consider the differences between agents when recommending niacin for dyslipidemia treatment...
  33. ncbi request reprint Study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters
    J M McKenney
    National Clinical Reseach Inc, Richmond, Virginia, USA
    J Clin Pharmacol 46:785-91. 2006
    ..At steady state, the coadministration of P-OM3 capsules did not appear to affect the pharmacokinetics of simvastatin tablets. The combination of P-OM3 capsules and simvastatin appeared to be well tolerated...
  34. ncbi request reprint Effect of omega-3-acid ethyl esters on the steady-state plasma pharmacokinetics of rosuvastatin in healthy adults
    Pritti Gosai
    Virginia Commonwealth University, 2809 Emerywood Parkway, Suite 140, Richmond, VA 23294, USA
    Expert Opin Pharmacother 9:2947-53. 2008
    ..Patients with persistent hypertriglyceridemia while on statin therapy may require adjunctive lipid-lowering therapy to meet treatment goals...
  35. ncbi request reprint The cost of treating dyslipidaemia using National Cholesterol Education Program (NCEP) guidelines
    J M McKenney
    Virginia Commonwealth University School of Pharmacy, Richmond, USA
    Pharmacoeconomics 14:19-28. 1998
    ..The mean cost to reach NCEP goals was consequently lowest for atorvastatin. Results from pharmacoeconomic studies of primary and secondary prevention are therefore in support of NCEP treatment guidelines for hypercholesterolaemia...
  36. ncbi request reprint Safety considerations with gastrointestinally active lipid-lowering drugs
    Terry A Jacobson
    Emory University, Office of Health Promotion and Disease Prevention, Atlanta, Georgia 30303, USA
    Am J Cardiol 99:47C-55C. 2007
    ..Overall, CAIs and BAS have excellent systemic safety profiles when used alone or in combination with other lipid-lowering drugs...
  37. doi request reprint Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia
    Kevin C Maki
    Provident Clinical Research, Glen Ellyn, Illinois, USA
    Am J Cardiol 102:429-33. 2008
    ..In conclusion, P-OM3 + simvastatin appears to be a useful therapeutic option for the management of mixed dyslipidemia...
  38. ncbi request reprint Understanding physician and consumer attitudes concerning cholesterol management: results from the National Lipid Association surveys
    Richard C Pasternak
    Massachusetts General Hospital, Boston, Massachusetts 02114 2696, USA
    Am J Cardiol 94:9F-15F. 2004
    ..Current attitudes of physicians and consumers are similar with regard to their recognition of the significance of cholesterol and CAD for health, but differ with regard to why patients do not take prescription medications...
  39. ncbi request reprint Safety considerations with fibrate therapy
    Michael H Davidson
    Rush University Medical Center, Chicago, Illinois, USA
    Am J Cardiol 99:3C-18C. 2007
    ....
  40. ncbi request reprint Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice
    Robert L Ohsfeldt
    Texas A and M Health Science Center, Department of Health Policy and Management, College Station, TX 77840, USA
    Am J Manag Care 12:S412-23. 2006
    ..The objective of the present study was to estimate the clinical effectiveness and cost-effectiveness of rosuvastatin compared with atorvastatin or simvastatin among high-risk patients as treated in routine clinical practice...
  41. ncbi request reprint Understanding practice patterns and low-density lipoprotein cholesterol goal attainment implications of switching patients from simvastatin in a health plan setting
    Caroline R Harley
    Health Economics and Outcomes, i3 Innovus, 12125 Technology Drive, Minnesota, MN 55244, USA
    Am J Manag Care 13:S276-81. 2007
    ....
  42. ncbi request reprint Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)
    Peter H Jones
    Baylor College of Medicine, 6565 Fannin Avenue, A 601, Houston, TX 77030, USA
    Am J Cardiol 92:152-60. 2003
    ..0 mmol/L was achieved by 79% to 92% in rosuvastatin groups compared with 52% to 81% in atorvastatin groups. Drug tolerability was similar across treatments...
  43. ncbi request reprint Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky 40213, USA
    Am J Cardiol 92:538-43. 2003
    ..At the higher doses, gemcabene significantly reduced LDL cholesterol levels in all patients with low HDL cholesterol...
  44. ncbi request reprint Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals
    James Shepherd
    Department of Pathological Biochemistry, Royal Infirmary, University of Glasgow, Scotland, United Kingdom
    Am J Cardiol 91:11C-17C; discussion 17C-19C. 2003
    ..001). A total of 71% of patients treated with rosuvastatin 10 mg who had triglyceride levels > or =200 mg/dL met both their LDL cholesterol and their non-high-density lipoprotein cholesterol goals...
  45. ncbi request reprint Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations
    Michael H Davidson
    Radiant Development, Chicago, Illinois, USA
    Am J Cardiol 96:556-63. 2005
    ..Most of those (75%) with cardiovascular disease in NEPTUNE II would be considered very high risk and candidates for aggressive therapy to reach the new optional treatment goals...
  46. ncbi request reprint Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia
    Peter H Jones
    Section of Atherosclerosis and Lipid Research, Baylor College of Medicine, Houston, Tex 77030, USA
    Am Heart J 149:e1. 2005
    ..The NASDAC study was designed to evaluate the safety and efficacy of atorvastatin at starting doses of 10, 20, 40, and 80 mg...
  47. ncbi request reprint Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003
    James Shepherd
    Atheroscler Suppl 5:115-23. 2004
  48. ncbi request reprint Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels
    Michael H Davidson
    Rush Presbyterian St Luke s Medical Center, Chicago, Illinois, USA
    J Am Coll Cardiol 48:1774-81. 2006
    ..This study was designed to evaluate the efficacy and safety of torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, in subjects with low high-density lipoprotein cholesterol (HDL-C) levels...